MMP Clinical Trials
CLINICAL PROTOCOLS OPEN FOR ENROLLMENT
CHIP/CCUS Natural History Protocol (Open/Recruiting)
PI: Neal Young
ID: NCT04102423
Contact: Ivana Darden, R.N., (301) 827-2988 ivana.darden@nih.gov
https://clinicaltrials.gov/ct2/show/NCT04102423?term=19-H-0139&draw=2&rank=1
Longitudinal Studies of Patient with FPDMM (Open Recruiting)
PI: Paul Liu
NCT03854318
Contact, Natalie T Deuitch, (301) 385-5205 natalie.deuitch@nih.gov
https://clinicaltrials.gov/ct2/show/NCT03854318?term=runx1+paul+liu&draw=2&rank=1
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (Open/Recruiting)
PI: Dennis Hickstein, M.D.
ID: NCT01861106
Contact: Dennis D Hickstein, M.D., (240) 760-6169 hicksted@mail.nih.gov
https://clinicaltrials.gov/ct2/show/NCT01861106?term=gata2&draw=2&rank=2
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia (Open/Recruiting)
PI: Nirali Shah, M.D.
ID: NCT03971799
Contact: Hati Kobusingye, (763) 406 4385 hkobusin@nmdp.org
Contact: Erin Leckrone, (763) 406-5124 eleckron@nmdp.org
https://clinicaltrials.gov/ct2/show/NCT03971799
Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies (Open/Recruiting)
PI: Christopher G. Kanakry, M.D.
ID: NCT04959175
Contact: Amy Chai, (301) 219-7105 amy.chai@nih.gov
https://clinicaltrials.gov/ct2/show/NCT04959175
Phase I/II Study De-Intensifying Exposure of Post-Transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-Haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies (Open/Recruiting)
PI: Christopher G. Kanakry, M.D.
ID: NCT03983850
Contact: Ashley DeVries, (301) 219-7230 ashley.devries@nih.gov
https://clinicaltrials.gov/ct2/show/NCT03983850?cond=GVHD&cntry=US&state=US%3AMD&draw=4&rank=21
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (Open/Recruiting)
PI: Steven Pavletic, M.D.
ID: NCT02356159
Contact: Ashley E Carpenter, (240) 858-3190 carpentera@mail.nih.gov
Contact: Steven Z Pavletic, M.D., (240) 760-6174 sp326h@nih.gov
https://clinicaltrials.gov/ct2/show/NCT02356159?term=palifermin+and+pavletic&draw=2&rank=1
Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) (Open/Recruiting)
PI: Rosandra Kaplan, M.D
ID: NCT02390752
Contact: Elaine W Thomas, (240) 858-7013 elaine.thomas@nih.gov
Contact: Rosandra N Kaplan, M.D., (240) 760-6198 kaplanrn@mail.nih.gov
https://clinicaltrials.gov/ct2/show/NCT02390752
Cancer in Inherited Bone Marrow Failure Syndromes (Open/Recruiting)
|
PI: Neelam Giri, M.D.
ID: NCT00027274
Contact: Stephanie M Steinbart, R.N., (800) 518-8474 stephanie.steinbart@nih.gov
Contact: Neelam Giri, M.D., (240) 276-7256 girin@mail.nih.gov
https://clinicaltrials.gov/ct2/show/NCT00027274?term=NCT00027274&draw=2&rank=1
CLINICAL PROTOCOLS SOON TO BE OPEN FOR ENROLLEMENT
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes (Expected to be open by March 1, 2022)
PI: Steven Pavletic, M.D.
ID: NCT05148234
Contact: Ashley E Carpenter, (240) 858-3190 carpentera@mail.nih.gov
https://clinicaltrials.gov/ct2/show/NCT05148234?term=NCT05148234&draw=2&rank=1
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome (Expected to be open by March 1, 2022)
PI: Dennis Hickstein, M.D.,
ID: NCT05027945
Contact: Dennis D Hickstein, M.D., (240) 760-6169 hicksted@mail.nih.gov
https://clinicaltrials.gov/ct2/show/NCT05027945?term=vexas&draw=2&rank=1
MDS Natural History and Biospecimen Acquisition Protocol (Pro 000661) (Expected to be open for accrual by March 1, 2022)
PI: Kathy McGraw, Ph.D.
ID: Pending
Contact: Kathy McGraw, Ph.D., (240) 760-7134 Kathy.mcgraw@nih.gov
Phase I/II study of Pacritinib, a JAK2/IRAK1/CSF1R/FLT3 inhibitor, in refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) (Expected to be open by June 1, 2022
PI: Noa G. Holtzman, M.D.
ID: Pending
Contact: Noa G. Holtzman, M.D., (301) 318-2298 noa.holtzman@nih.gov
A Phase I/II Trial of Eltanexor (KPT-8602) with Decitabine-Cedazuridine in Myelodysplastic Syndromes (Expected to be open by June 1, 2022)
PI: Steven Pavletic, M.D.
ID: Pending
Contact: Steven Z Pavletic, M.D., (240) 760-6174 sp326h@nih.gov
Phase I/II trial of pacritinib, a kinase inhibitor of CSF1R, JAK2, FLT3, and IRAK1, in adults and children ³ 12 years of age with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms (Expected to be open by July 1, 2022)
PI: Rosandra Kaplan, M.D.
ID: Pending
Contact: Rosandra Kaplan, M.D., (240) 760-6198 kaplanrn@mail.nih.gov